{"id":15709,"name":"Modi Ventures","slug":"modi-ventures","website":"https://www.modivc.com","hqGeo":"US","stageFocus":["Pre-Seed","Seed","Series A"],"sectorTags":["AI / ML","Healthcare","Developer Tools"],"excludedSectors":[],"checkSizeMin":null,"checkSizeMax":null,"thesisSummary":"Invests at the intersection of artificial intelligence and biology, backing founders building software and scientific infrastructure for life sciences. The firm is explicitly oriented toward AI plus bio convergence.","thesisNarrative":null,"logoUrl":null,"aumUsd":1000000000,"submissionUrl":null,"linkedinUrl":null,"twitterHandle":null,"portfolio":[{"companyName":"Serif Biomedicines","companyUrl":null,"stage":null,"sector":"Gene Editing","investmentYear":2026,"description":"Pioneering a new category of biotechnology to treat and prevent disease.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Imagenomix","companyUrl":null,"stage":"AI Diagnostics","sector":"Precision Medicine","investmentYear":2026,"description":"Imagenomix delivers rapid and affordable cancer diagnostic results through advanced AI capabilities so patients receive effective, targeted treatments for their specific cancer type.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Cytospire","companyUrl":null,"stage":null,"sector":"Cell Therapy","investmentYear":2026,"description":"Cytospire is developing next generation γδ T cell engagers into impactful cancer therapies.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Breye Therapeutics","companyUrl":null,"stage":null,"sector":"Therapeutics","investmentYear":2026,"description":"Breye Therapeutics provides treatment solutions for patients at risk of vision loss and blindness by developing orally administered therapies for patients with deteriorating vision from retinal vascular diseases within ophthalmology.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Exciva","companyUrl":null,"stage":null,"sector":"Therapeutics","investmentYear":2026,"description":"Exciva is developing a groundbreaking therapy that effectively and safely addresses neuropsychiatric symptoms of dementia including agitation/aggression in Alzheimer’s disease dementia.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Proxima","companyUrl":null,"stage":null,"sector":"AI Drug Discovery","investmentYear":2026,"description":"Proxima is pioneering the next generation of AI-driven drug discovery for proximity-based therapeutics.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Eridu","companyUrl":null,"stage":null,"sector":"AI Chip","investmentYear":2026,"description":"Eridu is the pioneer advancing the frontier in AI networking with a solution built from the ground up to deliver the bandwidth, performance and reliability at scale needed by AI data centers.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Early","companyUrl":null,"stage":"Diagnostics","sector":"Medical Devices","investmentYear":2025,"description":"Early brings early disease detection to the comfort of our homes with devices that are accurate, easy to use and beautiful.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"ProFound Therapeutics","companyUrl":null,"stage":"Drug Discovery","sector":"Therapeutics","investmentYear":2025,"description":"We have discovered a vast, expanded universe of novel proteins encoded by the human genome. In analyzing these proteins, we elucidate their respective biological functions, refining our understanding of the molecular underpinnings of human biology and disease.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Kamau Therapeutics","companyUrl":null,"stage":"Gene Editing","sector":"Therapeutics","investmentYear":2025,"description":"Kamau Therapeutics is a clinical-stage, next-generation gene correction company harnessing high efficiency targeted gene integration to develop a new class of therapies with the aim to cure a wide range of serious and life-threatening diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Brainomix","companyUrl":null,"stage":"Diagnostics","sector":"AI Software Platform","investmentYear":2025,"description":"Brainomix has revolutionized medical imaging with an AI-powered platform that automates validated imaging biomarkers—improving both diagnosis and treatment decisions.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Ypsilon Therapeutics","companyUrl":null,"stage":null,"sector":"Therapeutics","investmentYear":2025,"description":"Ypsilon Therapeutics develops next-generation cancer therapies: T-cell receptor mimic (TCRm) antibodies and bispecific T-cell engagers (TCEs) that selectively target and destroy solid tumors while sparing healthy tissue.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Lila Sciences","companyUrl":null,"stage":null,"sector":"AI Platform","investmentYear":2025,"description":"Building the world’s first scientific superintelligence platform and fully autonomous labs for life, chemical, and materials sciences.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Ignota Labs","companyUrl":null,"stage":null,"sector":"AI Drug Discovery","investmentYear":2025,"description":"Ignota Labs applies deep learning to bioinformatics and cheminformatics datasets to solve drug safety issues, rescuing promising but failing drugs and bringing new life to abandoned projects and new hope to patients.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Komo Biosciences","companyUrl":null,"stage":"Gene Editing","sector":"Therapeutics","investmentYear":2024,"description":"Komo Biosciences enables accelerated development and manufacturing of therapeutics by translating the utility of high-efficiency integrases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Elemind","companyUrl":null,"stage":null,"sector":"Digital Health","investmentYear":2024,"description":"Wearable neurotechnology that augments sleep, attention, and ultimately the human experience.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Rubedo","companyUrl":null,"stage":"Drug Discovery","sector":"Longevity","investmentYear":2024,"description":"Rubedo discovers and develops medicines to keep you biologically young.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Latus Bio","companyUrl":null,"stage":null,"sector":"Drug Discovery","investmentYear":2024,"description":"Latus Bio is developing curative medicines for neurological diseases.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Simple HealthKit","companyUrl":null,"stage":null,"sector":"Digital Health","investmentYear":2024,"description":"Simple HealthKit makes timely detection and world-class care accessible for anyone, from anywhere.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Groq, Inc","companyUrl":null,"stage":null,"sector":"AI Technology","investmentYear":2024,"description":"Groq provides fast AI inference in the cloud and in on-prem AI compute centers.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Pathpresenter","companyUrl":null,"stage":null,"sector":"AI Software Platform","investmentYear":2024,"description":"PathPresenter is an enterprise workflow platform powered by Microsoft Azure Cloud.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Glyphic Biotechnologies","companyUrl":null,"stage":null,"sector":"Protein Sequencing","investmentYear":2024,"description":"Glyphic Bio is redefining proteomics with next-generation protein sequencing.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Case 45","companyUrl":null,"stage":"Drug Discovery","sector":"AI Diagnostics","investmentYear":2024,"description":"Case 45 is building the most advanced precision AI model for oncology, rooted in cancer evolutionary biology.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Tandem Vet Care","companyUrl":null,"stage":null,"sector":"Veterinary","investmentYear":2024,"description":"Tandem’s combination of in-person clinic and online care is a unique way to maintain an ongoing relationship with us and pet health.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Outpace Bio","companyUrl":null,"stage":null,"sector":"Cell Therapy","investmentYear":2024,"description":"Outpace Bio is revolutionizing cell therapy with protein design to cure solid tumors.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Evity Technologies","companyUrl":null,"stage":null,"sector":"AI Platform","investmentYear":2024,"description":"Evity is building a new foundation for healthspan—an evidence-based longevity intelligence platform for healthcare systems.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Techion","companyUrl":null,"stage":null,"sector":"Digital Health","investmentYear":2024,"description":"Techion develops hardware and software to provide digital diagnostics for animals, people and our environment.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"March Biosciences","companyUrl":null,"stage":"Drug Discovery","sector":"Therapeutics","investmentYear":2024,"description":"March Biosciences is developing advanced cell therapies, targeting complex diseases like cancer and genetic disorders through precision medicine approaches.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Aether","companyUrl":null,"stage":null,"sector":"TechBio","investmentYear":2024,"description":"Aether uses its state of the art platform to rapidly engineer enzymes.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"General Proximity","companyUrl":null,"stage":"Drug Discovery","sector":"Longevity","investmentYear":2024,"description":"Developing the next generation of induced-proximity medicines.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Cytospire Therapeutics","companyUrl":null,"stage":"Series A","sector":"biotech","investmentYear":null,"description":"Biotech company developing therapeutics.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Unnatural Products","companyUrl":null,"stage":"Series A","sector":"biotech/synbio","investmentYear":null,"description":"Synthetic biology company.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Eridu Industries","companyUrl":null,"stage":"Series A","sector":"not clear from the available sources","investmentYear":null,"description":"Industrial/technology company.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Exciva Therapeutics","companyUrl":null,"stage":"Series B","sector":"biotech/neuroscience","investmentYear":null,"description":"Develops therapies for neuropsychiatric symptoms of dementia, including agitation and aggression in Alzheimer’s disease.","amountUsd":null,"relevanceNote":null,"fundName":null}],"partnerCount":1,"partners":[{"id":51204,"name":"Not specified in source","title":"GP","seniority":null,"focusTags":["AI","biology"],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]}],"funds":[{"id":595,"name":"Modi Ventures Fund III","vintageYear":2023,"sizeUsd":250000000,"status":"investing","focusAreas":[]}],"activity":{"lastInvestmentYear":2026,"investmentsLast12Months":14},"investorType":"vc","preferredApproach":"cold outreach ok","prefersFounderType":null,"oneClickPitchEnabled":false,"relatedFirms":[{"id":13762,"name":"NeuroNet Ventures","slug":"neuronet-ventures","logoUrl":null,"website":"https://neuronetgpo.com/","stageFocus":["Seed"],"sectorTags":["AI / ML","Other"],"hqGeo":"Chicago, IL"},{"id":11767,"name":"LiftScale Partners","slug":"liftscale-partners","logoUrl":null,"website":"https://weareliftscale.com/","stageFocus":["Pre-Seed"],"sectorTags":["Other","AI / ML","SaaS"],"hqGeo":"San Francisco, CA"},{"id":7722,"name":"Sheesha Finance","slug":"sheesha-finance","logoUrl":null,"website":"https://sheeshafinance.gitbook.io/","stageFocus":[],"sectorTags":["AI / ML","Developer Tools","Fintech"],"hqGeo":null},{"id":11323,"name":"Mountain Pine Capital","slug":"mountain-pine-capital","logoUrl":null,"website":"https://mountainpineholdings.com/","stageFocus":["Seed"],"sectorTags":["Consumer","Healthcare","Real Estate"],"hqGeo":"Salt Lake City, UT"},{"id":497,"name":"SBI Investment (SBI Group)","slug":"sbi-investment-sbi-group","logoUrl":null,"website":"https://www.sbinvestment.co.jp/","stageFocus":["Seed","Series A"],"sectorTags":["Fintech","Other","Developer Tools"],"hqGeo":"Tokyo, Japan"},{"id":3892,"name":"Madrona Pioneer Fund","slug":"madrona-pioneer-fund","logoUrl":null,"website":"https://www.madrona.com/","stageFocus":["Pre-Seed","Seed"],"sectorTags":["Other","Real Estate","SaaS","Enterprise","Security","Developer Tools"],"hqGeo":"Seattle, WA"}],"featuredIn":[{"slug":"pre-seed","displayName":"Pre-Seed Investors","pageType":"stage"},{"slug":"seed","displayName":"Seed Investors","pageType":"stage"},{"slug":"ai","displayName":"AI & ML Investors","pageType":"industry"},{"slug":"series-a","displayName":"Series A Investors","pageType":"stage"},{"slug":"healthcare","displayName":"Healthcare Investors","pageType":"industry"}],"fundraisingResources":[{"slug":"find-right-pre-seed-investors-b2b-saas","title":"How to Find the Right Pre-Seed Investors for Your B2B SaaS Startup"},{"slug":"how-to-find-investors","title":"How to Find Investors: A VC's Playbook for Founders"},{"slug":"how-vcs-help-portfolio-raise-follow-on","title":"How VCs Can Actually Help Their Portfolio Companies Raise Follow-On"}],"overviewNarrative":null,"portfolioNarrative":null,"seoTitle":null,"seoDescription":null,"lastVerifiedAt":"2026-10-22T15:10:19.196Z"}